|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Burris HA IIIrd, Moore MJ, Andersen J,
Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK,
Storniolo AM, Tarassoff P, et al: Improvements in survival and
clinical benefit with gemcitabine as first-line therapy for
patients with advanced pancreas cancer: A randomized trial. J Clin
Oncol. 15:2403–2413. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sant M, Allemani C, Santaquilani M, Knijn
A, Marchesi F and Capocaccia R; EUROCARE Working Group, :
EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999.
Results and commentary. Eur J Cancer. 45:931–991. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Demols A, Peeters M, Polus M, Marechal R,
Gay F, Monsaert E, Hendlisz A and Van Laethem JL: Gemcitabine and
oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic
adenocarcinoma: A phase II study. Br J Cancer. 94:481–485. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim SK, Kim H, Lee DH, Kim TS, Kim T,
Chung C, Koh GY, Kim H and Lim DS: Reversing the intractable nature
of pancreatic cancer by selectively targeting aldh-high,
therapy-resistant cancer cells. PLoS One. 8:e781302013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Herrera L, Bostrom B, Gore L, Sandler E,
Lew G, Schlegel PG, Aquino V, Ghetie V, Vitetta ES and Schindler J:
A phase 1 study of Combotox in pediatric patients with refractory
B-lineage acute lymphoblastic leukemia. J Pediatr Hematol Oncol.
31:936–941. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stirpe F and Battelli MG:
Ribosome-inactivating proteins: Progress and problems. Cell Mol
Life Sci. 63:1850–1866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lin JY, Tserng KY, Chen CC, Lin LT and
Tung TC: Abrin and ricin: New anti-tumour substances. Nature.
227:292–293. 1970. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zwierzina H, Bergmann L, Fiebig H, Aamdal
S, Schöffski P, Witthohn K and Lentzen H: The preclinical and
clinical activity of aviscumine: A potential anticancer drug. Eur J
Cancer. 47:1450–1457. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Voss C, Eyol E and Berger MR:
Identification of potent anticancer activity in Ximenia americana
aqueous extracts used by African traditional medicine. Toxicol Appl
Pharmacol. 211:177–187. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Voss C, Eyol E, Frank M, von der Lieth CW
and Berger MR: Identification and characterization of riproximin, a
new type II ribosome-inactivating protein with antineoplastic
activity from Ximenia americana. FASEB J. 20:1194–1196. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Horrix C, Raviv Z, Flescher E, Voss C and
Berger MR: Plant ribosome-inactivating proteins type II induce the
unfolded protein response in human cancer cells. Cell Mol Life Sci.
68:1269–1281. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bayer H, Essig K, Stanzel S, Frank M,
Gildersleeve JC, Berger MR and Voss C: Evaluation of riproximin
binding properties reveals a novel mechanism for cellular
targeting. J Biol Chem. 287:35873–35886. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Eyol E, Murtaga A, Zhivkova-Galunska M,
Georges R, Zepp M, Djandji D, Kleeff J, Berger MR and Adwan H: Few
genes are associated with the capability of pancreatic ductal
adenocarcinoma cells to grow in the liver of nude rats. Once Rep.
28:2177–2187. 2012. View Article : Google Scholar
|
|
17
|
Corrie PG: Cytotoxic chemotherapy:
Clinical aspects. Medicine. 36:24–28. 2008. View Article : Google Scholar
|
